Abstract CT131: Entrectinib inNTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct131
Abstract: Background Gene fusions involving NTRK (neurotrophic receptor tyrosine kinase) genes result in the expression of chimeric TRK proteins with uncontrolled kinase activity, leading to oncogenic transformation and unrestrained cancer cell proliferation, which confers oncogenic potential… read more here.
Keywords: fusion positive; cancer; cell; ntrk ... See more keywords
Updated efficacy and safety of zurlectrectinib in adult patients (pts) with locally advanced or metastatic NTRK fusion–positive (NTRK+) solid tumors.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.3112
Abstract: 3112 Background: NTRK gene fusion is one of the most defined driving factors of carcinogenesis, which occurs in various adult tumor types. Zurlectrectinib, a highly selective next-generation TRK tyrosine kinase inhibitor, previously demonstrated encouraging efficacy… read more here.
Keywords: adult; ntrk; adult pts; solid tumors ... See more keywords
From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2024.1329409
Abstract: Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. Two first-generation NTRK inhibitors (larotrectinib and entrectinib) are currently approved for the treatment of patients with solid… read more here.
Keywords: cancer; ntrk; analysis; real world ... See more keywords